We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-5.2%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$176M
AUM Growth
-$3.89M
(-2.2%)
Cap. Flow
+$11.2M
Cap. Flow
% of AUM
6.35%
Top 10 Holdings %
Top 10 Hldgs %
22.1%
Holding
256
New
24
Increased
39
Reduced
133
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
+$3.86M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$3.65M |
| 3 |
TSVT
2seventy bio
TSVT
|
+$3.13M |
| 4 |
uniQure
QURE
|
+$3.1M |
| 5 |
Embecta
EMBC
|
+$2.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AdaptHealth
AHCO
|
+$3.44M |
| 2 |
Elanco Animal Health
ELAN
|
+$2.97M |
| 3 |
Centene
CNC
|
+$2.7M |
| 4 |
iShares MBS ETF
MBB
|
+$2.05M |
| 5 |
Lantheus
LNTH
|
+$1.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.71% |
| 2 | Real Estate | 10.29% |
| 3 | Financials | 3.55% |
| 4 | Technology | 3.29% |
| 5 | Energy | 2.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WBA
1
DELISTED
Walgreens Boots Alliance
WBA
| $5M | 2.84% |
225,000
+145,000
| +181% | +$3.86M |
|
2
Rithm Capital
RITM
$5.26B
| $4.71M | 2.67% |
507,277
+15,578
| +3% | +$154K |
|
3
BioCryst Pharmaceuticals
BCRX
$2.31B
| $4.59M | 2.61% |
649,000
+79,000
| +14% | +$568K |
|
4
Harmony Biosciences
HRMY
$1.94B
| $4M | 2.27% |
122,000
+4,000
| +3% | +$139K |
|
5
iShares 1-3 Year Treasury Bond ETF
SHY
$25.7B
| $3.66M | 2.08% |
45,190
+18,397
| +69% | +$1.49M |
|
|
LKFT
6
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
| $3.63M | 2.06% |
105,000
+6,000
| +6% | +$234K |
|
7
Jazz Pharmaceuticals
JAZZ
$15.2B
| $3.43M | 1.95% |
26,500
-14,250
| -35% | -$1.9M |
|
8
Coherus Oncology
CHRS
$214M
| $3.41M | 1.94% |
912,500
| – | – |
|
9
Neurocrine Biosciences
NBIX
$17.2B
| $3.38M | 1.91% |
30,000
-6,500
| -18% | -$684K |
|
10
Pacira BioSciences
PCRX
$1.01B
| $3.16M | 1.79% |
103,000
+46,500
| +82% | +$1.68M |
|
|
11
Embecta
EMBC
$199M
| $3.12M | 1.77% |
207,000
+113,500
| +121% | +$2.13M |
|
|
EFC
12
Ellington Financial
EFC
$1.72B
| $2.98M | 1.69% |
239,271
| – | – |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.95M | 1.67% |
25,500
| – | – |
|
14
Ironwood Pharmaceuticals
IRWD
$637M
| $2.82M | 1.6% |
292,500
+135,000
| +86% | +$1.32M |
|
15
Amylyx Pharmaceuticals
AMLX
$1.89B
| $2.66M | 1.51% |
145,500
+37,500
| +35% | +$793K |
|
|
16
uniQure
QURE
$2.71B
| $2.63M | 1.49% |
391,500
+344,000
| +724% | +$3.1M |
|
|
TSVT
17
DELISTED
2seventy bio
TSVT
| $2.58M | 1.46% |
657,500
+477,500
| +265% | +$3.13M |
|
18
Crinetics Pharmaceuticals
CRNX
$8.88B
| $2.44M | 1.38% |
82,000
+35,000
| +74% | +$721K |
|
19
UroGen Pharma
URGN
$1.95B
| $2.31M | 1.31% |
165,000
+12,500
| +8% | +$201K |
|
|
RVNC
20
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.18M | 1.24% |
+190,000
| New | +$3.65M |
|
|
DX
21
Dynex Capital
DX
$2.91B
| $2.17M | 1.23% |
181,492
+28,000
| +18% | +$355K |
|
22
Invesco S&P 500 Pure Value ETF
RPV
$1.58B
| $2.15M | 1.22% |
29,285
-1,926
| -6% | -$149K |
|
23
iShares Russell 1000 Value ETF
IWD
$81.9B
| $2.15M | 1.22% |
14,193
-812
| -5% | -$129K |
|
24
United Therapeutics
UTHR
$22.5B
| $2.03M | 1.15% |
9,000
| – | – |
|
25
Insmed
INSM
$23.3B
| $2.02M | 1.15% |
80,000
-15,000
| -16% | -$343K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, AlphaCentric Advisors held 256 positions worth $176M, down 2.2% from $180M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $11.2M of net new capital in Q3 2023, opening 24 new positions and adding to 39 existing holdings. Its largest new stake was Revance Therapeutics, Inc.: 190,000 shares worth $2.18M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 60% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $1.9M trimmed.
- AlphaCentric Advisors's largest Q3 2023 buy was Revance Therapeutics, Inc.: 190,000 shares worth $2.18M.
- AlphaCentric Advisors added most to Walgreens Boots Alliance in Q3 2023, an estimated $3.86M increase.
- AlphaCentric Advisors's biggest Q3 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $1.9M.
- AlphaCentric Advisors fully exited AdaptHealth in Q3 2023, selling an estimated $3.44M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $176M portfolio in Q3 2023.
- AlphaCentric Advisors opened 24 new positions and closed 21 in Q3 2023.
- AlphaCentric Advisors's portfolio value fell 2.2% quarter-over-quarter to $176M.
Based on AlphaCentric Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.